These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 19538176)

  • 1. Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery.
    Fu Q; Sun J; Zhang W; Sui X; Yan Z; He Z
    Recent Pat Anticancer Drug Discov; 2009 Nov; 4(3):262-72. PubMed ID: 19538176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. nab-Paclitaxel mechanisms of action and delivery.
    Yardley DA
    J Control Release; 2013 Sep; 170(3):365-72. PubMed ID: 23770008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Albumin-bound paclitaxel: a next-generation taxane.
    Gradishar WJ
    Expert Opin Pharmacother; 2006 Jun; 7(8):1041-53. PubMed ID: 16722814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein nanoparticles as drug carriers in clinical medicine.
    Hawkins MJ; Soon-Shiong P; Desai N
    Adv Drug Deliv Rev; 2008 May; 60(8):876-85. PubMed ID: 18423779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient delivery of therapeutic agents by using targeted albumin nanoparticles.
    Kouchakzadeh H; Safavi MS; Shojaosadati SA
    Adv Protein Chem Struct Biol; 2015; 98():121-43. PubMed ID: 25819278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiation-guided drug delivery to mouse models of lung cancer.
    Hariri G; Yan H; Wang H; Han Z; Hallahan DE
    Clin Cancer Res; 2010 Oct; 16(20):4968-77. PubMed ID: 20802016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel.
    Petrelli F; Borgonovo K; Barni S
    Expert Opin Pharmacother; 2010 Jun; 11(8):1413-32. PubMed ID: 20446855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors.
    Lluch A; Alvarez I; Muñoz M; Seguí MÁ; Tusquets I; García-Estévez L
    Crit Rev Oncol Hematol; 2014 Jan; 89(1):62-72. PubMed ID: 24071503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel.
    Stinchcombe TE
    Nanomedicine (Lond); 2007 Aug; 2(4):415-23. PubMed ID: 17716129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer.
    Guarneri V; Dieci MV; Conte P
    Expert Opin Pharmacother; 2012 Feb; 13(3):395-406. PubMed ID: 22263900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved anticancer effects of albumin-bound paclitaxel nanoparticle via augmentation of EPR effect and albumin-protein interactions using S-nitrosated human serum albumin dimer.
    Kinoshita R; Ishima Y; Chuang VTG; Nakamura H; Fang J; Watanabe H; Shimizu T; Okuhira K; Ishida T; Maeda H; Otagiri M; Maruyama T
    Biomaterials; 2017 Sep; 140():162-169. PubMed ID: 28651144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetics and Exposure-Response Analysis of nab-Paclitaxel in Pediatric Patients With Recurrent or Refractory Solid Tumors.
    Li Y; Kassir N; Chen N; Wang X; Palmisano M; Zhou S
    Clin Pharmacol Drug Dev; 2021 Feb; 10(2):115-130. PubMed ID: 32459889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel therapeutic potential in targeting microtubules by nanoparticle albumin-bound paclitaxel in hepatocellular carcinoma.
    Zhou Q; Ching AK; Leung WK; Szeto CY; Ho SM; Chan PK; Yuan YF; Lai PB; Yeo W; Wong N
    Int J Oncol; 2011 Mar; 38(3):721-31. PubMed ID: 21240457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Uniqueness of Albumin as a Carrier in Nanodrug Delivery.
    Spada A; Emami J; Tuszynski JA; Lavasanifar A
    Mol Pharm; 2021 May; 18(5):1862-1894. PubMed ID: 33787270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors.
    Abu-Khalaf MM; Baumgart MA; Gettinger SN; Doddamane I; Tuck DP; Hou S; Chen N; Sullivan C; Lezon-Geyda K; Zelterman D; Hatzis C; Deshpande H; Digiovanna MP; Azodi M; Schwartz PE; Harris LN
    Cancer; 2015 Jun; 121(11):1817-26. PubMed ID: 25649370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using nanotechnology to improve the characteristics of antineoplastic drugs: improved characteristics of nab-paclitaxel compared with solvent-based paclitaxel.
    Foote M
    Biotechnol Annu Rev; 2007; 13():345-57. PubMed ID: 17875482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic sensitivity of paclitaxel to its delivery vehicles drives distinct clinical outcomes of paclitaxel formulations.
    Li Y; Chen N; Palmisano M; Zhou S
    Mol Pharm; 2015 Apr; 12(4):1308-17. PubMed ID: 25714793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of breast cancer with nanoparticle albumin-bound (nab)-paclitaxel combination regimens: a clinical review.
    Chirgwin J; Chua SL
    Breast; 2011 Oct; 20(5):394-406. PubMed ID: 21839635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of albumin on drug delivery--new applications on the horizon.
    Elsadek B; Kratz F
    J Control Release; 2012 Jan; 157(1):4-28. PubMed ID: 21959118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors.
    Stinchcombe TE; Socinski MA; Walko CM; O'Neil BH; Collichio FA; Ivanova A; Mu H; Hawkins MJ; Goldberg RM; Lindley C; Dees EC
    Cancer Chemother Pharmacol; 2007 Oct; 60(5):759-66. PubMed ID: 17285317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.